Stocks Health care RNAZ
NASDAQ · Health careTranscode Therapeutics, Inc. (RNAZ)
It posted a net loss of $42.8M. In fiscal 2025 capital spending exceeded operating cash flow by $19.5M. At June 30, 2026 it held $8.4M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 14, 2026.
Key facts about Transcode Therapeutics, Inc.
- Net worth
- Transcode Therapeutics, Inc. has a market value (market cap) of $26.1M at the latest share price, and shareholders' equity of -$27.7M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2025 operations used $19.5M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 14, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Transcode Therapeutics, Inc.'s next report is expected around November 13, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What Transcode Therapeutics, Inc. does
Transcode Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker RNAZ.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$34.7M | -$52.59 | -$19.5M |
| 2024 | n/a | -$16.8M | -$1,336.63 | -$13.4M |
| 2023 | n/a | -$18.5M | -$96,944.24 | -$18.1M |
| 2022 | n/a | -$17.6M | -$1,013,128.56 | -$15.9M |
| 2021 | n/a | -$6.8M | -$607,877.14 | -$5.5M |
| 2021 | n/a | -$2.3M | -$382,737.46 | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Transcode Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 1, 2026Material agreement8-KTransCode Therapeutics made an $840,975 prepayment to Yorkville to obtain a waiver for an amortization event under its convertible notes.
- September 28, 2026Other event 8-K
- September 11, 2026
- August 14, 2026
- August 3, 2026Activist stake changed SCHEDULE 13D/A
- August 3, 2026
- July 28, 2026Passive stake (5% or more) SCHEDULE 13G
- July 28, 2026Passive stake (5% or more) SCHEDULE 13G
- July 28, 2026Passive stake (5% or more) SCHEDULE 13G
- July 27, 2026Activist stake changed SCHEDULE 13D/A
Insider trades
What the people running Transcode Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| August 3, 2026 | Defj, LLC10% owner | Exercised options | 11,813,859 | - |
| August 3, 2026 | Defj, LLC10% owner | Exercised options | 2,020,582 | - |
Who owns RNAZ
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Defj, LLC13D, may seek influence with 1 related filers | 83.9% | August 3, 2026 |
| Unleash Immuno Oncolytics, Inc.13G, passive | 9.94% | July 28, 2026 |
| YA II PN, Ltd.13G, passive with 7 related filers | 9.9% | April 20, 2026 |
| Elena Rosa Braci13G, passive | 6.17% | July 28, 2026 |
| Thomas A. Fitzgerald13D, may seek influence | 5.5% | June 21, 2024 |
| Daniel Eduardo Katzman13G, passive | 5.16% | July 28, 2026 |
| Thomas Joseph Tracy13D, may seek influence | 5% | March 20, 2025 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 8 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Yorkville Advisors Global, LP | 19,639 | new |
| Vanguard Capital Management LLC | 6,545 | 0 |
| Vanguard Fiduciary Trust Co | 2,982 | 0 |
| UBS Group AG | 2,888 | -5,407 |
| Fmr LLC | 706 | new |
| Tower Research Capital LLC (TRC) | 677 | +449 |
| Wells Fargo & Company | 55 | 0 |
| SBI Securities Co., Ltd. | 12 | 0 |
Insiders
1 insiders reported holding 14,134,481 shares in total, about $21.8M at the last price.
| Holder | Shares |
|---|---|
| Defj, LLC10% owner | 14,134,481 |
Questions about RNAZ
What does Transcode Therapeutics, Inc. do?
Transcode Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as RNAZ. Its shares trade on NASDAQ under the ticker RNAZ.
What is Transcode Therapeutics, Inc.'s net worth?
Transcode Therapeutics, Inc. has a market value (market cap) of $26.1M at the latest share price, and shareholders' equity of -$27.7M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Transcode Therapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $42.8M.
When did Transcode Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 14, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the material agreement from October 1, 2026.
When is Transcode Therapeutics, Inc.'s next earnings report?
Transcode Therapeutics, Inc.'s next report is expected around November 13, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare RNAZ with
Follow RNAZ
Get an email when Transcode Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Transcode Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.